Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

BC43

Inter-amer 30 (BC43)

Inter-amer 30
から:
次の項目別のソート:
 Showing the most relevant articles for your search:LSE:BC43
日付受信時刻ニュースソース見出しコード企業名
2002/11/1323 : 09UK RegulatoryRebecca O. Kendall Announces Retirement; Robert A. Armitage Promoted to Lilly Senior Vice President, General CounselLSE:BC43Inter-amer 30
2002/11/0918 : 30UK RegulatoryEli Lilly and CompanyLSE:BC43Inter-amer 30
2002/11/0821 : 30UK RegulatoryLilly Outlines to Wall Street Its Strategy To Realize Its Growth Opportunities and Deliver Superior Earnings Growth Over the LonLSE:BC43Inter-amer 30
2002/11/0816 : 19UK RegulatoryEli Lilly and CompanyLSE:BC43Inter-amer 30
2002/11/0803 : 08UK RegulatoryEli Lilly and CompanyLSE:BC43Inter-amer 30
2002/11/0601 : 02UK RegulatoryEli Lilly and CompanyLSE:BC43Inter-amer 30
2002/11/0122 : 47UK RegulatoryEli Lilly and CompanyLSE:BC43Inter-amer 30
2002/10/3100 : 03UK RegulatoryEli Lilly and CompanyLSE:BC43Inter-amer 30
2002/10/2923 : 00UK RegulatoryCymbalta Data Suggest Rapid and Sustained Response by First Week of TherapyLSE:BC43Inter-amer 30
2002/10/2321 : 10UK Regulatory3rd Quarter ResultsLSE:BC43Inter-amer 30
2002/10/2216 : 01UK RegulatoryAlimta Continues To Show Versatility in Treating Different CancersLSE:BC43Inter-amer 30
2002/10/2205 : 15UK RegulatoryDividend DeclarationLSE:BC43Inter-amer 30
2002/10/1816 : 00UK RegulatoryCombining Innovative Therapies for Optimal Cancer Care; Effectiveness of Gemzar-Based Combination Regimens is Topic of WorkshopLSE:BC43Inter-amer 30
2002/10/0123 : 10UK RegulatoryNewly Published Study Demonstrates Sustained Efficacy of Evista -raloxifene HCl- in Reducing Risk of Spinal FracturesLSE:BC43Inter-amer 30
2002/09/2606 : 59UK RegulatoryLilly Asserts The New England Journal of Medicine ``Sounding Board'' Opinion Article Attempts to Turn Back the Clock on Care ofLSE:BC43Inter-amer 30
2002/09/2506 : 39UK RegulatoryRe AllianceLSE:BC43Inter-amer 30
2002/09/2409 : 05UK RegulatoryRe AllianceLSE:BC43Inter-amer 30
2002/09/2022 : 07UK RegulatoryStatement reLSE:BC43Inter-amer 30
2002/09/1723 : 34UK RegulatoryLilly Launches World's Largest Severe Sepsis Clinical Trial; 11,000 Patients to be Enrolled in Study of Xigris Use in Patients wLSE:BC43Inter-amer 30
2002/09/1702 : 02UK RegulatoryFDA Issues Approvable Letter for Lilly's Cymbalta for Treatment of Depression; From the Makers of Prozac, Cymbalta Will Offer NeLSE:BC43Inter-amer 30
2002/09/1623 : 04UK RegulatoryMiscellaneousLSE:BC43Inter-amer 30
2002/09/0323 : 08UK RegulatoryTadalafil for the Treatment of Erectile Dysfunction Receives Positive Recommendation From the Australian Drug Evaluation CommittLSE:BC43Inter-amer 30
2002/08/2704 : 11UK RegulatoryRegulatory ApprovalLSE:BC43Inter-amer 30
2002/08/2700 : 44UK RegulatoryMiscellaneousLSE:BC43Inter-amer 30
2002/08/1504 : 02UK RegulatoryMiscellaneousLSE:BC43Inter-amer 30
2002/08/1501 : 56UK RegulatoryMiscellaneousLSE:BC43Inter-amer 30
2002/08/1422 : 29UK RegulatoryFDA Issues Approvable Letter for Strattera for ADHD; Strattera Would Give Patients, Families and Physicians a New Treatment OptiLSE:BC43Inter-amer 30
2002/08/0116 : 23UK RegulatoryLilly's Xigris Becomes First and Only Medical Product Approved for BIPA Payment in Medicare PatientsLSE:BC43Inter-amer 30
2002/07/3023 : 50UK RegulatoryRe AllianceLSE:BC43Inter-amer 30
2002/07/2605 : 03UK RegulatoryLilly ICOS LLCLSE:BC43Inter-amer 30
 Showing the most relevant articles for your search:LSE:BC43

最近閲覧した銘柄

Delayed Upgrade Clock